SIC
ATYR

SJS Investment Consulting’s aTyr Pharma ATYR Stock Holding History

SJS Investment Consulting’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$125 Buy
208
+166
+395% +$108 ﹤0.01% 2564
2026
Q1 		$33 Buy
+42
New +$35 ﹤0.01% 2310

Other funds holding ATYR

CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
KWA
Kingswood Wealth Advisors San Diego, California $2.48B AUM 36.19% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
AHL
Abel Hall LLC Baton Rouge, Louisiana $579M AUM 54.21% 1-Year Est. Return
TCOT
Trust Company of Toledo Holland, Ohio $1.2B AUM 33.38% 1-Year Est. Return
GIA
Gladstone Institutional Advisory Palm Beach Gardens, Florida $3.16B AUM 29.04% 1-Year Est. Return
AFC
Ares Financial Consulting Calabasas, California $139M AUM
VR
Vision Retirement Ridgewood, New Jersey $414M AUM
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return

SJS Investment Consulting's ATYR Position: Q2 2026 in Review

SJS Investment Consulting increased its aTyr Pharma (ATYR) stake by 395% in Q2 2026, buying an estimated $108 and bringing the position to 208 shares worth $125. The position accounts for ﹤0.01% of the portfolio, ranked #2564.

SJS Investment Consulting first reported a position in ATYR in Q1 2026 and has held it in 2 quarters since. 16 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

  • SJS Investment Consulting held 208 shares of aTyr Pharma worth $125 as of Q2 2026.
  • SJS Investment Consulting bought 166 aTyr Pharma shares in Q2 2026, an estimated $108.
  • aTyr Pharma made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2564 holding.
  • SJS Investment Consulting first reported a position in aTyr Pharma in Q1 2026 and has held it in 2 quarters since.
  • 16 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.